ClinicalTrials.gg
CompletedNCT07600762Updated Jul 20, 2026

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants

A Phase 1 interventional study of Nacresertib and Placebo for Nacresertib in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Japanese male or female; 18 to 65 years of age at the time of screening.
  • Japanese participant must be first-or second-generation Japanese of full Japanese parentage. First-generation participants will have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent. Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent.
  • is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenth decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy, any cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.
  • History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption [e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection, etc.].
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Nacresertib

    Participants will receive a single dose of Nacresertib

    Drug: Nacresertib

  • Placebo comparator
    Placebo for Nacresertib

    Participants will receive a single dose of Placebo for Nacresertib

    Drug: Placebo for Nacresertib

Interventions

  • Oral tablet

  • DrugPlacebo for Nacresertib

    Oral tablet

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Nacresertib

    Cmax of Nacresertib

    Time frame: Up to 9 Days

  2. Time to Cmax (Tmax) of Nacresertib

    Tmax of Nacresertib

    Time frame: Up to 9 Days

  3. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of Nacresertib

    AUCt of Nacresertib

    Time frame: Up to 9 Days

  4. AUC From Time 0 to the Time Infinity (AUCinf) of Nacresertib

    AUCinf of Nacresertib

    Time frame: Up to 9 Days

  5. Terminal Phase Elimination Rate Constant (Beta) of Nacresertib

    Beta of Nacresertib

    Time frame: Up to 9 Days

  6. Terminal Phase Elimination Half-Life (t1/2) of Nacresertib

    t1/2 of Nacresertib

    Time frame: Up to 9 Days

  7. Number of Participants Experiencing Adverse Events (AEs)

    Any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment

    Time frame: Up to 42 Days

07

Study locations

1 site
  • CenExel ACT- Anaheim Clinical Trials /ID# 282482
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2026 to primary completion in Jun 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
May 22, 2026
StartActual
Apr 21, 2026
Primary completionActual
Jun 17, 2026
CompletionActual
Jun 17, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07600762
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Apr 21, 2026
Primary completion
Jun 17, 2026
Completion
Jun 17, 2026
Last update
Jul 20, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nacresertib

Start the discussion